Debrisoquine oxidation phenotype and susceptibility to lung cancer.

doi:10.1111/j.1365-2125.1990.tb03608.x

Back to search

Article

Debrisoquine oxidation phenotype and susceptibility to lung cancer.

British journal of clinical pharmacology - 1 Jan 1990

Speirs C J, Murray S, Davies D S, Biola Mabadeje A F, Boobis A R

Abstract excerpt

1. It has been suggested that poor metabolisers of debrisoquine are at reduced risk of developing lung cancer from smoking cigarettes. This has been investigated in 82 patients with established cancer of the lung. 2. The frequency of poor metaboliser subjects was not different from that in the no...

Topics

Adenocarcinoma
Aged
Aged, 80 and over
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Debrisoquin
Female
Humans
Isoquinolines
Lung Neoplasms
Male
Middle Aged
Oxidation-Reduction
Phenotype
Risk
Smoking

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.